### South Africa

**Population 2018**: 58 million

### Tuberculosis profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>301 (215–400)</td>
<td>520 (373–691)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>177 (127–235)</td>
<td>306 (219–406)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>11 (7.2–16)</td>
<td>19 (12–28)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>21 (20–23)</td>
<td>37 (35–39)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>42 (30–57)</td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Proportion (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases</td>
<td>3.4% (2.5–4.3)</td>
</tr>
<tr>
<td>Previously treated cases</td>
<td>7.1% (4.8–9.5)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2018

- **Total new and relapse**: 227,999
  - % tested with rapid diagnostics at time of diagnosis: 71%
  - % with known HIV status: 90%
  - % pulmonary: 89%
  - % bacteriologically confirmed MDR/RR: 70%
  - % children aged 0-14 years: 7%
  - % women: 37%
  - % men: 56%
- **Total cases notified**: 235,652

### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2018**: 76% (57–110)
- **TB patients facing catastrophic total costs**: 22% (14–30)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 22%

### TB/HIV care in new and relapse TB patients, 2018

- **Patients with known HIV status who are HIV-positive**: 120,862 (59%)
  - on antiretroviral therapy: 104,625 (87%)

### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance
  - New cases: 92%
  - Previously treated cases: 94%

### Laboratory-confirmed cases

- **MDR/RR-TB**: 13,199
- **XDR-TB**: 553

### Patients started on treatment

- **MDR/RR-TB**: 9,558
- **XDR-TB**: 539

### Treatment success rate and cohort size

- **New and relapse cases registered in 2017**: 77% (240,332)
- **Previously treated cases, excluding relapse, registered in 2017**: 59% (6,508)
- **HIV-positive TB cases registered in 2017**: 75% (134,672)
- **MDR/RR-TB cases started on second-line treatment in 2016**: 54% (11,159)
- **XDR-TB cases started on second-line treatment in 2016**: 58% (601)

### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 65%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 59% (54–65)

### TB financing, 2019

- **National TB budget (US$ millions)**: 240
  - Funding source: 87% domestic, 13% international, 0% unfunded

---

*Ranges represent uncertainty intervals

**MDR** is TB resistant to rifampicin and isoniazid; **RR** is TB resistant to rifampicin

**MDR/RR-TB** cases are tested for resistance to second-line drugs

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.